Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
Previous Symbol
CUSIP45337C10
Phone302-498-6700
Debt
Debt-to-Equity Ratio0.01
Current Ratio4.02
Quick Ratio4.01
Price-To-Earnings
Trailing P/E Ratio103.52
Forward P/E Ratio154.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.54 billion
Price / Sales9.18
Cash Flow$0.8695 per share
Price / Cash Flow76.19
Book Value$7.73 per share
Price / Book8.57
Profitability
EPS (Most Recent Fiscal Year)$0.64
Net Income$-313,140,000.00
Net Margins-6.07%
Return on Equity2.23%
Return on Assets1.59%
Miscellaneous
Employees1,208
Outstanding Shares212,810,000
Market Cap$14.10 billion
OptionableOptionable
Incyte (NASDAQ:INCY) Frequently Asked Questions
What is Incyte's stock symbol?
Incyte trades on the NASDAQ under the ticker symbol "INCY."
How were Incyte's earnings last quarter?
Incyte Co. (NASDAQ:INCY) issued its quarterly earnings data on Tuesday, October, 30th. The biopharmaceutical company reported $0.38 EPS for the quarter, missing the Zacks' consensus estimate of $0.40 by $0.02. The biopharmaceutical company earned $449.68 million during the quarter, compared to analyst estimates of $448.34 million. Incyte had a negative net margin of 6.07% and a positive return on equity of 2.23%. Incyte's revenue was up 17.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.19 earnings per share. View Incyte's Earnings History.
When is Incyte's next earnings date?
What price target have analysts set for INCY?
22 brokerages have issued 1-year price targets for Incyte's stock. Their forecasts range from $70.00 to $172.00. On average, they anticipate Incyte's stock price to reach $95.0653 in the next year. This suggests a possible upside of 43.5% from the stock's current price. View Analyst Price Targets for Incyte.
What is the consensus analysts' recommendation for Incyte?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.
What are Wall Street analysts saying about Incyte stock?
Here are some recent quotes from research analysts about Incyte stock:
- 1. According to Zacks Investment Research, "Incyte’s lead drug Jakafi continues to maintain momentum for the company as the underlying patient demand for the drug remains strong. Incyte’s sNDA, seeking a label expansion of Jakafi for the treatment of steroid-refractory acute GVHD, has been accepted for Priority Review by the FDA. The agency has set a target action date of Feb 24, 2019. An approval will further boost sales. The recent FDA approval of Olumiant 2 mg, for which Incyte received a milestone payment from Lilly, is a positive. However, Incyte suffered a setback with failure of the phase III ECHO-301 study, evaluating epacadostat in combination with Keytruda. Further, the approval of the 4mg dose of baricitinib is doubtful. Moreover, Incyte’s dependence on only Jakafi is a concern as well. Shares have underperformed the industry in the year so far." (12/11/2018)
- 2. Raymond James analysts commented, "We are reiterating our Strong Buy rating for Incyte. This morning, the company announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for Jakafi for the treatment of patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The priority review grants a 6 month review period by the FDA, resulting in a PDUFA date of approximately March 25, 2019. Based on positive data from the REACH1 study, we remain confident regarding Incyte’s expansion into the steroid refractory GVHD market, which we estimate to be a ~$500 million market opportunity in the U.S." (10/25/2018)
- 3. Cantor Fitzgerald analysts commented, ". We are increasing our price target to $74 from $73 and reiterating our Neutral rating on INCY. At the ongoing ESMO, INCY provided updated Fight-202 results in cholangiocarcinoma, which looked superior to the previously disclosed initial data. Additionally, in a late-breaker presentation, Novartis (NVS, Not Covered) reported Phase II results from its MET inhibitor capmatinib in MET-mutated advanced non-small cell lung cancer (NSCLC) patients. Note that NVS received worldwide rights for capmatinib from INCY. NVS reported promising response rate data that compare favorably to earlier reported results from any MET inhibitors." (10/21/2018)
- 4. JPMorgan Chase & Co. analysts commented, "INCY’s 1Q print/report (initial thoughts here; slides here) this morning was relatively uneventful. Following the success of REACH1 in acute GVHD, management is planning a regulatory filing in 3Q18 (recall Jakafi has BTD status) with plans for an immediate launch upon approval. Also, as previously disclosed, a filing for the FGFR inhibitor in cholangiocarcinoma is still anticipated in 2019, pending final data follow- up (interim data at recent investor day). We’re maintaining our OW given shares are trading at a discount to our DCF derived fair value for the base business. With that said, we suspect it will require some significant execution on the relatively broad pipeline for investors to more actively re-engage with the story." (8/1/2018)
Has Incyte been receiving favorable news coverage?
News headlines about INCY stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Incyte earned a news impact score of 1.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are some of Incyte's key competitors?
Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and HedgePath Pharmaceuticals (HPPI).
Who are Incyte's key executives?
Incyte's management team includes the folowing people:
- Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 58)
- Mr. David W. Gryska M.B.A., MBA, Exec. VP & CFO (Age 63)
- Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 55)
- Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 51)
- Mr. Paul Trower, Principal Accounting Officer & VP of Fin. (Age 48)
Who are Incyte's major shareholders?
Incyte's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc (8.64%), BlackRock Inc. (7.09%), Capital International Investors (3.56%), Manning & Napier Group LLC (2.17%), BB Biotech AG (1.79%) and Pictet Asset Management Ltd. (0.88%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Institutional Ownership Trends for Incyte.
Which institutional investors are selling Incyte stock?
INCY stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Capital International Investors, Capital World Investors, Mitsubishi UFJ Trust & Banking Corp, Teachers Advisors LLC, Massachusetts Financial Services Co. MA and Shikiar Asset Management Inc.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, David W Gryska, Paul Trower, Paula J Swain, Reid M Huber and Vijay K Iyengar. View Insider Buying and Selling for Incyte.
Which institutional investors are buying Incyte stock?
INCY stock was purchased by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, First Trust Advisors LP, BlackRock Inc., AQR Capital Management LLC, Manning & Napier Group LLC, Worldquant Millennium Quantitative Strategies LLC, Sector Gamma AS and Eaton Vance Management. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.
How do I buy shares of Incyte?
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Incyte's stock price today?
One share of INCY stock can currently be purchased for approximately $66.25.
How big of a company is Incyte?
Incyte has a market capitalization of $14.10 billion and generates $1.54 billion in revenue each year. The biopharmaceutical company earns $-313,140,000.00 in net income (profit) each year or $0.64 on an earnings per share basis. Incyte employs 1,208 workers across the globe.
What is Incyte's official website?
How can I contact Incyte?
Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]
MarketBeat Community Rating for Incyte (NASDAQ INCY)
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
